Rethink Aging
At resTORbio, we are developing innovative medicines that target the biology of aging to prevent or treat aging-related diseases.
Learn More
Science
Aging is the most significant risk factor for most chronic diseases.
Strong scientific evidence suggests that aging is regulated by specific biochemical pathways. Medicines that target these biochemical pathways, such as the TORC1 pathway, may prevent or treat a variety of aging-related diseases.
Learn More
We aim to be a leading biopharmaceutical company focused on preventing or treating aging-related diseases.
Our Pipeline
resTORbio’s lead clinical program is selectively targeting TORC1, an evolutionarily conserved pathway that contributes to the age-related decline in function of multiple organ systems, including immune, neurologic and cardiac function.
Inhibition of TORC1 has the potential to improve the function of aging organ systems and address multiple aging related diseases.
Inhibition of TORC1 has the potential to improve the function of aging organ systems and address multiple aging related diseases.
Clinical Trials
Our goal is to discover, develop and make available innovative medicines to help older adults.